Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lupus nephritis: current issues.

Literature DB >> 12922947

Lupus nephritis: current issues.

Abstract

Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2003 PMID： 12922947 PMCID： PMC1754664 DOI： 10.1136/ard.62.9.795

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

35 in total

Review 1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors: W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal: Arthritis Rheum Date: 1999-07

2. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.

Authors: J N Boletis; J P Ioannidis; K A Boki; H M Moutsopoulos
Journal: Lancet Date: 1999-08-14 Impact factor: 79.321

3. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

Authors: D I Daikh; B K Finck; P S Linsley; D Hollenbaugh; D Wofsy
Journal: J Immunol Date: 1997-10-01 Impact factor: 5.422

4. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease.

Authors: R A Brodsky; M Petri; B D Smith; E J Seifter; J L Spivak; M Styler; C V Dang; I Brodsky; R J Jones
Journal: Ann Intern Med Date: 1998-12-15 Impact factor: 25.391

5. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center.

Authors: D L Huong; T Papo; H Beaufils; B Wechsler; O Blétry; A Baumelou; P Godeau; J C Piette
Journal: Medicine (Baltimore) Date: 1999-05 Impact factor: 1.889

6. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network.

Authors: M A Dooley; S Hogan; C Jennette; R Falk
Journal: Kidney Int Date: 1997-04 Impact factor: 10.612

7. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients.

Authors: P G Vlachoyiannopoulos; F B Karassa; K X Karakostas; A A Drosos; H M Moutsopoulos
Journal: Lupus Date: 1993-10 Impact factor: 2.911

8. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients.

Authors: H C Nossent; S C Henzen-Logmans; T M Vroom; J H Berden; T J Swaak
Journal: Arthritis Rheum Date: 1990-07

9. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

Authors: R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón
Journal: Medicine (Baltimore) Date: 1993-03 Impact factor: 1.889

Lupus nephritis: current issues.

Review 1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

2. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.

3. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

4. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease.

5. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center.

6. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network.

7. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients.

8. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients.

9. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

10. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans.

Review 1. [Glucocorticoid therapy in collagen diseases diseases].

2. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

3. Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis.

Review 4. Novel therapeutic agents in clinical development for systemic lupus erythematosus.